var data={"title":"Azathioprine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Azathioprine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5689?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=azathioprine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Azathioprine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=azathioprine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Azathioprine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708623\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Chronic immunosuppression with azathioprine, a purine antimetabolite, increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Health care providers using this drug should be very familiar with this risk, as well as with the mutagenic potential to both men and women, and with possible hematologic toxicities. Inform patients of the risk of malignancy with azathioprine.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138216\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Azasan;</li>\n      <li>Imuran</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138217\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Azathioprine;</li>\n      <li>Imuran;</li>\n      <li>Mylan-Azathioprine;</li>\n      <li>Teva-Azathioprine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138263\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Immunosuppressant Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138221\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients with intermediate thiopurine methyltransferase (TPMT) activity may be at risk for increased myelosuppression; those with low or absent TPMT activity receiving conventional azathioprine doses are at risk for developing severe, life-threatening myelotoxicity. Dosage reductions are recommended for patients with reduced TPMT activity; consider discontinuing in patients with abnormal blood counts that do not respond to dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplantation:</b> IV, Oral: Initial therapy following transplant: 3 to 5 mg/kg once daily (usually given as a single daily dose), then 1 to 3 mg/kg (usual dose: 50 to 150 mg/day) once daily maintenance. <b>Note:</b> The primary use of azathioprine in the setting of renal transplantation has largely been replaced by the mycophenolic acid derivatives (Lee 2012). If other antiproliferative agents become intolerable, patients may be safely converted to a maintenance dose of azathioprine (El-Agroudy 2009; Lou 2004; Wuthrich 2000; Zhu 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: 1 mg/kg/day (50 to 100 mg) given once daily or divided twice daily; after 6 to 8 weeks, may increase by 0.5 mg/kg every 4 weeks until response or up to 2.5 mg/kg/day; an adequate trial should be a minimum of 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Reduce dose by 0.5 mg/kg (~25 mg daily) every 4 weeks until lowest effective dose is reached; optimum duration of therapy not specified; may be discontinued abruptly (monitor for delayed toxicities).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: <b>Note:</b> IV is indicated only in patients unable to tolerate oral medications (dosing should be transitioned from IV to oral as soon as tolerated):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: ~1 mg/kg/day (50 to 100 mg) given once daily or divided twice daily; after 6 to 8 weeks, may increase by 0.5 mg/kg every 4 weeks until response or up to 2.5 mg/kg/day; an adequate trial should be a minimum of 12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: Reduce dose by 0.5 mg/kg (~25 mg daily) every 4 weeks until lowest effective dose is reached; optimum duration of therapy not specified; may be discontinued abruptly (monitor for delayed toxicities)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Crohn disease, remission maintenance or reduction of steroid use (off-label use):</b> Oral: 2 to 3 mg/kg/day (Lichtenstein 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dermatomyositis/polymyositis, adjunctive management (off-label use):</b> Oral: 50 mg/day in conjunction with prednisone; increase by 50 mg/week to total dose of 2 to 3 mg/kg/day (Briemberg 2003); <b>Note:</b> Onset of beneficial effects may take 3 to 6 months; however, may be preferred over methotrexate in patients with pulmonary or hepatic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) (off-label use):</b> Oral: 2 mg/kg/day for 6 months (Ribi 2008). Additional data may be necessary to further define the role of azathioprine in the management of this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis (autoimmune) (off-label use): </b>IV, Oral: 1 mg/kg/day (usual dose: 50 mg once daily) in combination with corticosteroids; may increase to 2 mg/kg/day in patients who relapse or do not respond (AASLD [Manns 2010]; Lamers 2010). Most patients who are in complete remission for at least one year may continue azathioprine (without corticosteroids) at 2 mg/kg/day without relapse (Johnson 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Immune thrombocytopenia, chronic (refractory or relapsed) (off-label use):</b> Oral: 1 to 2 mg/kg/day; maximum dose: 150 mg/day (Provan 2010). Initial response is observed at 30 to 90 days; may take up to 6 months for peak response (Neunert 2011; Provan 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lupus nephritis, maintenance (off-label use):</b> Oral: Initial: 2 mg/kg/day; may reduce to 1.5 mg/kg/day after 1 month (if proteinuria &lt;1 g/day and serum creatinine stable) (Moroni 2006) <b>or</b> target dose: 2 mg/kg/day (Hahn 2012; Houssiau 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple sclerosis (off-label use): </b>Oral: 2 to 3 mg/kg/day (Casetta 2007; Fernandez 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis, recurrent (off-label use):</b> Oral: 150 mg once daily for 2 to 3 months, then 100 mg once daily to suppress clinical symptoms (Marcolongo 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Psoriasis (off-label use): </b>Oral: Initial: 0.5 mg/kg/day, if no occurrence of cytopenia after 6 to 8 weeks of therapy, may increase by 0.5 mg/kg/day every 4 weeks until response; usual dosage: 75 to 150 mg/day (AAD [Menter 2009])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ulcerative colitis, remission maintenance or reduction of steroid use (off-label use):</b> Oral: 1.5 to 2.5 mg/kg/day (Kornbluth 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uveitis (off-label use): </b>Oral: 2 to 3 mg/kg/day given either alone or in conjunction with corticosteroids and/or immunosuppressants (Pacheco 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant use with allopurinol:</b> Reduce azathioprine dose to one-third or one-fourth the usual dose when used concurrently with allopurinol. Patients with low or absent TPMT activity may require further dose reductions or discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49335045\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=azathioprine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Azathioprine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Uveitis (off- label use): </b>Oral: 1 to 3.2 mg/kg/day either alone or in conjunction with corticosteroids and/or immunosuppressants (Goebel 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138222\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138223\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer&rsquo;s labeling; however, oliguric patients, particularly those with tubular necrosis in the immediate post-transplant period (deceased donor transplant) may have delayed clearance and typically receive lower doses. The following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &gt;50 mL/minute: No adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl 10 to 50 mL/minute: Administer 75% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;10 mL/minute: Administer 50% of normal dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis (partially dialyzable; ~45% removed in 8 hours): Administer 50% of normal dose; supplement: 0.25 mg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CRRT: Administer 75% of normal dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673236\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6730683\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rapid WBC count decrease, persistently low WBC count, or serious infection: Reduce dose or temporarily withhold treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Severe toxicity (hematologic or other) in renal transplantation: May require discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease): Permanently discontinue. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138195\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Azasan: 75 mg, 100 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imuran: 50 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138180\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24672764\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Imuran: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138198\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Most commonly administered once daily. Administering tablets after meals or in divided doses may decrease adverse GI events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Infusion is usually administered over 30 to 60 minutes. Infusion time is dependent upon the final volume after dilution. While normally given over 30 to 60 minutes, it may be infused over 5 minutes up to over 8 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130888\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) when compounding. Double gloving and a gown are required during IV administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138197\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Renal transplantation:</b> Adjunctive therapy in prevention of rejection of kidney transplants</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations</i>: While azathioprine is FDA approved for adjunctive therapy in prevention of rejection after renal transplantation, it is no longer recommended as a first-line agent. The KDIGO clinical practice guidelines for care of kidney transplant recipients recommend a combination of maintenance immunosuppressive medications as maintenance therapy, including a calcineurin inhibitor and an antiproliferative agent (mycophenolate preferred) with or without corticosteroids. Azathioprine is recommended as a second-line antiproliferative agent for prevention of acute rejection (KDIGO [Kasiske 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rheumatoid arthritis:</b> Treatment of active rheumatoid arthritis (RA), to reduce signs and symptoms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475162\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Crohn disease; Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome); Hepatitis (autoimmune); Immune thrombocytopenia, chronic (adults); Lupus nephritis (maintenance phase); Multiple sclerosis; Pericarditis, recurrent; Psoriasis; Uveitis (adults); Uveitis (children/adolescents); Adjunct in prevention of rejection of solid organ (nonrenal) transplants (other less toxic therapies may be preferred [eg, mycophenolate]; Ulcerative colitis (UC) (remission maintenance or reduction of steroid use); Dermatomyositis/polymyositis; Erythema multiforme; Pemphigus vulgaris</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138271\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AzaTHIOprine may be confused with azaCITIDine, azidothymidine, azithromycin, Azulfidine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imuran may be confused with Elmiron, Enduron, Imdur, Inderal, Tenormin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Azathioprine is metabolized to mercaptopurine; concurrent use of these commercially-available products has resulted in profound myelosuppression.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138187\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined; dependent upon dose, duration, indication, and concomitant therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Malaise</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea and vomiting (rheumatoid arthritis: 12%), diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia (renal transplant: &gt;50%; rheumatoid arthritis: 28%), neoplasia (renal transplant 3% [other than lymphoma], 0.5% [lymphoma]), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity, increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Increased susceptibility to infection (renal transplant 20%; rheumatoid arthritis &lt;1%; includes bacterial, fungal, protozoal, viral, opportunistic, and reactivation of latent infections)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Myalgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute myelocytic leukemia, alopecia, anemia, arthralgia, bone marrow depression, hemorrhage, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatosplenic T-cell lymphomas, hepatotoxicity (idiosyncratic) (Chalasani, 2014), hypersensitivity, hypotension, interstitial pneumonitis (reversible), JC virus infection, macrocytic anemia, malignant lymphoma, malignant neoplasm of skin, negative nitrogen balance, pancreatitis, pancytopenia, progressive multifocal leukoencephalopathy, skin rash, steatorrhea, Sweet's syndrome (acute febrile neutrophilic dermatosis)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138202\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to azathioprine or any component of the formulation; pregnancy (in patients with rheumatoid arthritis [see Pregnancy Considerations]); patients with rheumatoid arthritis and a history of treatment with alkylating agents (eg, cyclophosphamide, chlorambucil, melphalan) may have a prohibitive risk of malignancy with azathioprine treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138184\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: The frequency of gastrointestinal adverse effects (nausea and vomiting) may be decreased with dividing dose or administering after meals. Gastrointestinal hypersensitivity with severe nausea and vomiting has been reported; diarrhea, rash, fever, malaise, myalgia, hypotension, and liver enzyme abnormalities may also occur. Symptoms usually develop within the first several weeks of treatment and are generally reversible upon discontinuation; may recur upon rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic toxicity: Dose-related hematologic toxicities (leukopenia, thrombocytopenia, and anemias, including macrocytic anemia and/or pancytopenia) may occur; may be severe and/or delayed. Thiopurine methyltransferase (TPMT) genotyping or phenotyping may help to identify patients who are at an increased risk for developing azathioprine toxicity. Patients with intermediate TPMT activity may be at increased risk for hematologic toxicity at conventional azathioprine doses; patients with low or absent TPMT activity are at risk for severe, life-threatening myelotoxicity. Myelosuppression may be more severe with renal transplants undergoing rejection. Monitor CBC with differential and platelets weekly during the first month, then twice a month for 2 months, then monthly (or more frequently if clinically indicated). May require treatment interruption or dose reduction. Leukopenia does not correlate with therapeutic effect and the dose should not be increased intentionally to lower the white blood cell count.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (transaminase, bilirubin, and/or alkaline phosphatase elevations) may occur, usually in renal transplant patients. Usually occurs within 6 months of transplant and is normally reversible with discontinuation. Monitor liver function periodically. Rarely, hepatic sinusoidal obstruction syndrome (SOS; formerly called veno-occlusive disease [VOD]) has been reported; discontinue if hepatic SOS is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Chronic immunosuppression increases the risk of serious, sometimes fatal, infections (bacterial, viral, fungal, protozoal, and opportunistic), including reactivation of latent infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: <b>[US Boxed Warning]: Chronic immunosuppression with azathioprine (a purine antimetabolite), increases the risk of malignancy. Malignancies reported have included post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Health care providers using this medication should be very familiar with this risk, as well as with the mutagenic potential to both men and women, and with possible hematologic toxicities. Patients should be informed of the risk for malignancy development.</b> HSTCL is a rare white blood cell cancer that is usually fatal and has predominantly occurred in adolescents and young adults treated for Crohn disease or ulcerative colitis and receiving TNF blockers (eg, adalimumab, certolizumab pegol, etanercept, golimumab), azathioprine, and/or mercaptopurine. Most cases of HSTCL have occurred in patients treated with a combination of immunosuppressant agents, although there have been reports of HSTCL in patients receiving azathioprine or mercaptopurine monotherapy. Renal transplant patients are known to be at increased risk for malignancy (eg, skin cancer, lymphoma), the risk is increased with aggressive immunosuppression. Limit sun and ultraviolet light exposure and use appropriate sun protection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: Cases of JC virus-associated infection resulting in progressive multifocal leukoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including azathioprine (some cases have been fatal). Risk factors for PML include treatment with immunosuppressants and immune system impairment. Consider a diagnosis of PML in any patient presenting with new-onset neurological manifestations; consultation with a neurologist as clinically indicated may be warranted. Consider decreasing the degree of immunosuppression with respect to the risk of organ rejection in transplant patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; TPMT deficiency: Patients with genetic deficiency of TPMT are more sensitive to myelosuppressive effects. Patients with intermediate TPMT activity may be at risk for increased myelosuppression; those with low or absent TPMT activity are at risk for developing severe and life-threatening hematologic toxicity. TPMT genotyping or phenotyping may assist in identifying patients at risk for developing toxicity. Consider TPMT testing in patients with abnormally low CBC unresponsive to dose reduction. TPMT testing does not substitute for CBC monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mercaptopurine: Azathioprine is metabolized to mercaptopurine; concomitant use may result in profound myelosuppression and should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; TPMT or xanthine oxidase inhibitors: Patients on concurrent therapy with drugs which may inhibit TPMT (eg, olsalazine) or xanthine oxidase (eg, allopurinol) may be sensitive to myelosuppressive effects. Dose adjustment of azathioprine may be recommended when used concurrently with allopurinol; patients with low or absent TPMT activity may require further dose reductions or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Immune response to vaccines may be diminished.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced health care provider: <b>[US Boxed Warning]: Should be prescribed by health care providers familiar with the risks, including hematologic toxicities and mutagenic potential. </b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298801\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138189\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9026&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the metabolism of Thiopurine Analogs.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Allopurinol: May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. More specifically, allopurinol may increase mercaptopurine serum concentrations and promote formation of active thioguanine nucleotides. Management: Reduce the azathioprine dose to one third to one quarter of the usual dose if used concomitantly with allopurinol, and monitor closely for systemic toxicity (particularly hematologic toxicity, nausea, and vomiting).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-TNF Agents: May enhance the adverse/toxic effect of Thiopurine Analogs. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased.<b> Exceptions: </b>Lenalidomide; Pomalidomide; Thalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: AzaTHIOprine may enhance the hepatotoxic effect of Cyclophosphamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Febuxostat: May increase the serum concentration of AzaTHIOprine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">InFLIXimab: May enhance the adverse/toxic effect of AzaTHIOprine. Specifically, the risk for T-cell non-Hodgkin's lymphoma (including hepatosplenic T-cell lymphoma) may be increased. InFLIXimab may increase serum concentrations of the active metabolite(s) of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: AzaTHIOprine may enhance the myelosuppressive effect of Mercaptopurine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Oral Inhalation): May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients extra closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin (Systemic): May increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased. Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfamethoxazole: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the myelosuppressive effect of AzaTHIOprine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): AzaTHIOprine may enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live).  Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): AzaTHIOprine may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138191\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1620142\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Azathioprine crosses the placenta in humans; congenital anomalies, immunosuppression, hematologic toxicities (lymphopenia, pancytopenia), and intrauterine growth retardation have been reported. Women of childbearing potential should avoid becoming pregnant during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Intrauterine growth retardation and preterm delivery are also reported in pregnancies following a kidney transplant. Stable immunosuppression is required in pregnant women who have had a kidney transplant and an increased risk of fetal malformations has not been observed with azathioprine; doses &le;2 mg/kg/day are recommended (Durst 2015; Hou 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although contraindicated by the manufacturer, available guidelines suggest that use of azathioprine is acceptable for the treatment of rheumatoid arthritis (Flint 2016). Azathioprine may also be used for the adjunctive treatment of lupus nephritis in pregnant women (Hahn 2012). Both guidelines recommend doses &le;2 mg/kg/day during pregnancy (Flint 2016; Hahn 2012). Agents other than azathioprine are recommended for the treatment of immune thrombocytopenia (Neunert 2011) and inflammatory bowel disease (van der Woude 2015) in pregnant women.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The National Transplantation Pregnancy Registry (NTPR) is a registry which follows pregnancies which occur in maternal transplant recipients or those fathered by male transplant recipients. The NTPR encourages reporting of pregnancies following solid organ transplant by contacting them at 877-955-6877 or NTPR@giftoflifeinstitute.org.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1620144\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Azathioprine is excreted in breast milk. Due to potential for serious adverse reactions in the nursing infant, breastfeeding is not recommended by the manufacturer. Although there are theoretical concerns of adverse events in nursing infants, available guidelines do not recommend mothers be discouraged from breastfeeding during therapy (Durst 2015; Flint 2016)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138193\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (weekly during first month, twice monthly for months 2 and 3, then monthly thereafter; monitor more frequently with dosage modifications), total bilirubin, liver function tests (every 3 months), creatinine clearance, monitor for signs/symptoms of infection and malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss). Azathioprine has been associated with skin cancer with long-term use after renal transplantation. Patients taking azathioprine for a prolonged time period should avoid sun exposure and be monitored for skin cancer regularly.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">TPMT genotyping or phenotyping: Consider testing in all patients with a lower threshold for testing in those with abnormally low CBC unresponsive to dose reduction. Patients with intermediate TPMT activity may be at an increased risk of bone marrow suppression; consider empirically reducing the dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Crohn disease or ulcerative colitis (off-label uses): In addition to the above, monitor CBC with differential weekly for 1 month, then biweekly for 1 month, followed by monitoring every 1 to 2 months throughout the course of therapy; monitor more frequently if symptomatic (ACR [Lichtenstein 2009]; Kornbluth 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The American Gastroenterological Association suggests routine TPMT testing (enzymatic or genotype) to guide thiopurine dosing in adult patients initiated on thiopurines. The AGA further suggests reactive thiopurine metabolite monitoring to guide therapy changes in adult patients treated with active inflammatory bowel disease or patients experiencing adverse effects potentially due to thiopurine toxicity (targeted 6-thioguanine level between 230 to 450 pmol/8 x 10<sup>8</sup> RBCs) (Feuerstein 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138183\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Azathioprine is an imidazolyl derivative of mercaptopurine; metabolites are incorporated into replicating DNA and halt replication; also block the pathway for purine synthesis (Taylor 2005). The 6-thioguanine nucleotide metabolites appear to mediate the majority of azathioprine&rsquo;s immunosuppressive and toxic effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138201\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Immune thrombocytopenia (oral): Initial response: 30 to 90 days; Peak response: 30 to 120 days (Neunert 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; metabolized to 6-mercaptopurine via glutathione S-transferase (GST) reduction. Further metabolized (in the liver and GI tract) via three major pathways: Hypoxanthine guanine phosphoribosyltransferase (to active metabolites: 6-thioguanine-nucleotides, or 6-TGNs), xanthine oxidase (to inactive metabolite: 6-thiouric acid), and thiopurine methyltransferase (TPMT) (to inactive metabolite: 6-methylmercaptopurine)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Azathioprine and mercaptopurine: Variable: ~2 hours (Taylor 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: Oral: 1 to 2 hours (including metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138204\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (AzaTHIOprine Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $300.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Azasan Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $1,898.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $846.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (AzaTHIOprine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $211.09</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imuran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $803.10</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F138206\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aza-Q (DE);</li>\n      <li>Azadus (TH);</li>\n      <li>Azafalk (DE);</li>\n      <li>Azafrine (KR);</li>\n      <li>Azamun (AE, AU, MY, NZ, SA, TW);</li>\n      <li>Azamune (GB);</li>\n      <li>Azanin (JP);</li>\n      <li>Azapin (AU);</li>\n      <li>Azapress (ZA, ZW);</li>\n      <li>Azaprin (AE, KW, QA, SA);</li>\n      <li>Azaprine (KR);</li>\n      <li>Azarekhexal (EE);</li>\n      <li>Azarex (DE);</li>\n      <li>Azathiodura (DE);</li>\n      <li>Azatioprina (PE);</li>\n      <li>Azatioprina Wellcome (IT);</li>\n      <li>Azatrilem (MX);</li>\n      <li>Azopi (IL);</li>\n      <li>Azoran (IN);</li>\n      <li>Azostal (LK);</li>\n      <li>Colinsan (DE);</li>\n      <li>Immuthera (KR);</li>\n      <li>Imuger (IE);</li>\n      <li>Imunen (BR);</li>\n      <li>Imuprin (AE, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, EG, ET, FI, GH, GM, GN, GY, HK, IQ, IR, JM, JO, KE, KW, LR, LY, MA, ML, MR, MT, MU, MW, NE, NG, OM, PR, SA, SC, SD, SL, SN, SR, SY, TH, TN, TT, TW, TZ, UG, YE, ZM, ZW);</li>\n      <li>Imuprine (NZ);</li>\n      <li>Imuran (AE, AR, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CL, CN, CO, CY, CZ, EC, EE, EG, ET, GB, GH, GM, GN, GR, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, NZ, OM, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VN, YE, ZM, ZW);</li>\n      <li>Imurek (AT, CH, DE);</li>\n      <li>Imurel (DK, ES, FI, FR, IS, NO, SE, VN);</li>\n      <li>Renzat (PH);</li>\n      <li>Thioprine (AU);</li>\n      <li>Transimune (IN);</li>\n      <li>Zaprine (ZA);</li>\n      <li>Zytrim (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines, &ldquo;Guidelines for Monitoring Drug Therapy in Rheumatoid Arthritis,&rdquo; <i>Arthritis Rheum</i>, 1996, 39(5):723-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/8639168/pubmed\" target=\"_blank\" id=\"8639168\">8639168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anstey AV, Wakelin S, and Reynolds NJ, &ldquo;Guidelines for Prescribing Azathioprine in Dermatology,&rdquo; <i>Br J Dermatol</i>, 2004, 151(6):1123-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/15606506/pubmed\" target=\"_blank\" id=\"15606506\">15606506</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnold DM, Nazi I, Santos A, et al, &ldquo;Combination Immunosuppressant Therapy for Patients With Chronic Refractory Immune Thrombocytopenic Purpura,&rdquo; <i>Blood</i>, 2010, 115(1):29-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/19897578/pubmed\" target=\"_blank\" id=\"19897578\">19897578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97, 177.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azasan (azathioprine) [prescribing information]. Wilmington, NC: Salix pharmaceuticals Inc; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azathioprine injection [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; August 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baum D, Bernstein D, Starnes VA, et al, &ldquo;Pediatric Heart Transplantation at Stanford: Results of a 15-Year Experience,&rdquo; <i>Pediatrics</i>, 1991, 88(2):203-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/1861916/pubmed\" target=\"_blank\" id=\"1861916\">1861916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beissert S, Werfel T, Frieling U, et al, &quot;A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Pemphigus,&quot; <i>Arch Dermatol</i>, 2006, 142(11):1447-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/17116835/pubmed\" target=\"_blank\" id=\"17116835\">17116835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briemberg HR and Amato AA, &ldquo;Dermatomyositis and Polymyositis,&rdquo; <i>Curr Treat Options Neurol</i>, 2003, 5(5):349-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/12895397/pubmed\" target=\"_blank\" id=\"12895397\">12895397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brookes MJ and Green JR, &ldquo;Maintenance of Remission in Crohn's Disease: Current and Emerging Therapeutic Options,&rdquo; <i>Drugs</i>, 2004, 64(10):1069-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/15139787/pubmed\" target=\"_blank\" id=\"15139787\">15139787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis (review). <i>Cochrane Database of Syst Rev</i>. 2007;(4):CD003982</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/24935270/pubmed\" target=\"_blank\" id=\"24935270\">24935270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheble JM, Gaburri PD, De Souza AF, et al, &ldquo;Long-Term Results With Azathioprine Therapy in Patients With Corticosteroid-Dependent Crohn's Disease: Open-Label Prospective Study,&rdquo; <i>J Gastroenterol Hepatol</i>, 2007, 22(2):268-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/17295882/pubmed\" target=\"_blank\" id=\"17295882\">17295882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dassopoulos T, Sultan S, Falck-Ytter YT, et al. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1464-1478.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/24267475/pubmed\" target=\"_blank\" id=\"24267475\">24267475</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durst JK, Rampersad RM. Pregnancy in women with solid-organ transplants: a review. <i>Obstet Gynecol Surv</i>. 2015;70(6):408-418.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/26115649/pubmed\" target=\"_blank\" id=\"26115649\">26115649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19017277\"></a>El-Agroudy AE, El-Dahshan KF, Wafa EW, et al. Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression. <i>Nephrology (Carlton)</i>. 2009;14(2):255-261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/19017277/pubmed\" target=\"_blank\" id=\"19017277\">19017277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandez O, Fernandez V, De Ramon E. Azathioprine and methotrexate in multiple sclerosis. <i>J Neurol Sci</i>. 2004;223(1):29-34</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. <i>Gastroenterology.</i> 2017;153(3):827-834. doi: 10.1053/j.gastro.2017.07.032.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/28780013/pubmed\" target=\"_blank\" id=\"28780013\">28780013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flint J, Panchal S, Hurrell A, et al; BSR and BHPR Standards, Guidelines and Audit Working Group.. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. <i>Rheumatology (Oxford)</i>. 2016;55(9):1693-1697.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/26750124/pubmed\" target=\"_blank\" id=\"26750124\">26750124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goebel JC, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. <i>Br J Ophthalmol</i>. 2011;95(2):209-213</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hou S. Pregnancy in renal transplant recipients. <i>Adv Chronic Kidney Dis</i>. 2013;20(3):253-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/23928390/pubmed\" target=\"_blank\" id=\"23928390\">23928390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houssiau FA, D'Cruz D, Sangle S, &ldquo;Azathioprine versus Mycophenolate Mofetil for Long-Term Immunosuppression in Lupus Nephritis: Results from the MAINTAIN Nephritis Trial,&rdquo; <i>Ann Rheum Dis</i>, 2010, 69(12):2083-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/20833738/pubmed\" target=\"_blank\" id=\"20833738\">20833738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imuran (azathioprine) [prescribing information]. Roswell, GA: Sebela Pharmaceuticals Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imuran (azathioprine) [product monograph]. Concord, Ontario, Canada: Triton Pharma Inc; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7666914\"></a>Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. <i>N Engl J Med</i>. 1995;333(15):958-963.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/7666914/pubmed\" target=\"_blank\" id=\"7666914\">7666914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones RR, &quot;Azathioprine Therapy in the Management of Persistent Erythema Multiforme,&quot; <i>Br J Dermatol</i>, 1981, 105(4):465-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/7295560/pubmed\" target=\"_blank\" id=\"7295560\">7295560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. <i>Kidney Int</i>. 2010;77(4):299-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/7295560/pubmed\" target=\"_blank\" id=\"7295560\">7295560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20068560\"></a>Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. <i>Am J Gastroenterol.</i> 2010;105(3):501-523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/20068560/pubmed\" target=\"_blank\" id=\"20068560\">20068560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20400196\"></a>Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. <i>J Hepatol</i>. 2010;53(1):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/20400196/pubmed\" target=\"_blank\" id=\"20400196\">20400196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23135563\"></a>Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. <i>Am J Health Syst Pharm</i>. 2012;69(22):1961-1975.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/23135563/pubmed\" target=\"_blank\" id=\"23135563\">23135563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Abreu MT, Cohen R, et al, &ldquo;American Gastroenterological Association Institute Medical Position Statement on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease,&rdquo; <i>Gastroenterology</i>, 2006, 130(3):935-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/16530531/pubmed\" target=\"_blank\" id=\"16530531\">16530531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lichtenstein GR, Hanauer SB, and Sandborn WJ, &ldquo;Management of Crohn's Disease in Adults,&rdquo; <i>Am J Gastroenterol</i>, 2009, 104(2):465-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/19174807/pubmed\" target=\"_blank\" id=\"19174807\">19174807</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15518756\"></a>Lou HX, Vathsala A. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression. <i>Transplant Proc</i>. 2004;36(7):2090-2091.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/15518756/pubmed\" target=\"_blank\" id=\"15518756\">15518756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maisch B, Seferovi&#263; PM, Risti&#263; AD, et al; Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. <i>Eur Heart J</i>. 2004;25(7):587-610.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20513004\"></a>Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. <i>Hepatology</i>. 2010;51(6):2193-2213.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/20513004/pubmed\" target=\"_blank\" id=\"20513004\">20513004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcolongo R, Russo R, Laveder F, Noventa F, Agostini C. Immunosuppressive therapy prevents recurrent pericarditis. <i>J Am Coll Cardiol</i>. 1995;26(5):1276-1279.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/7594043/pubmed\" target=\"_blank\" id=\"7594043\">7594043</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matalon ST, Ornoy A, and Lishner M, et al, &ldquo;Review of the Potential Effects of Three Commonly Used Antineoplastic and Immunosuppressive Drugs (Cyclophosphamide, Azathioprine, Doxorubicin on the Embryo and Placenta),&rdquo; <i>Reprod Toxicol</i>, 2004, 18(2):219-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/15019720/pubmed\" target=\"_blank\" id=\"15019720\">15019720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. <i>J Am Acad Dermatol</i>. 2009;61(3):451-485</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. <i>Blood</i>. 2011;117(16):4190-4207.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/21325604/pubmed\" target=\"_blank\" id=\"21325604\">21325604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis [published correction appears in <i>Ocul Immunol Inflamm</i>. 2009;17(6):438]. <i>Ocul Immunol Inflamm</i>. 2008;16(4):161-165.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T- cell lymphoma in patients receiving TNF-&alpha; Inhibitor therapy: expanding the groups at risk. <i>Eur J Gastroenterol Hepatol</i>. 2011; 23(12):1150-1156.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/21941193/pubmed\" target=\"_blank\" id=\"21941193\">21941193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petri M, &ldquo;Immunosuppressive Drug Use in Pregnancy,&rdquo; <i>Autoimmunity</i>, 2003, 36(1):51-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/12765471/pubmed\" target=\"_blank\" id=\"12765471\">12765471</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. <i>Blood</i>. 2010;115(2):168-186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/19846889/pubmed\" target=\"_blank\" id=\"19846889\">19846889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18240234\"></a>Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. <i>Arthritis Rheum.</i> 2008;58(2):586-594. doi: 10.1002/art.23198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/18240234/pubmed\" target=\"_blank\" id=\"18240234\">18240234</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandborn WJ, &ldquo;A Review of Immune Modifier Therapy for Inflammatory Bowel Disease: Azathioprine, 6-mercaptopurine, Cyclosporine, and Methotrexate,&rdquo; <i>Am J Gastroenterol</i>, 1996, 91(3):423-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/8633486/pubmed\" target=\"_blank\" id=\"8633486\">8633486</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon L, Lipman AG, Jacox A, et al, &ldquo;Guideline for the Management of Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain,&rdquo; 2nd ed, Glenview IL, American Pain Society, 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. <i>Crit Rev Oncol Hematol</i>. 2005;56(1):23-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/16039869/pubmed\" target=\"_blank\" id=\"16039869\">16039869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-&alpha; biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. <i>Gastroenterology</i>. 2013;145(6):1459-1463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/24267474/pubmed\" target=\"_blank\" id=\"24267474\">24267474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 12, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van der Woude CJ, Ardizzone S, Bengtson MB, et al; European Crohn&rsquo;s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. <i>J Crohns Colitis</i>. 2015;9(2):107-124.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/25602023/pubmed\" target=\"_blank\" id=\"25602023\">25602023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiendl H, Toyka KV, Rieckmann P, et al, &ldquo;Basic and Escalating Immunomodulatory Treatments in Multiple Sclerosis: Current Therapeutic Recommendations,&rdquo; <i>J Neurol</i>, 2008, 255(10):1449-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/19005625/pubmed\" target=\"_blank\" id=\"19005625\">19005625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10910450\"></a>W&uuml;thrich RP, Cicvara S, Amb&uuml;hl PM, Binswanger U. Randomized trial of conversion from mycophenolate mofetil to azathioprine 6 months after renal allograft transplantation. <i>Nephrol Dial Transplant</i>. 2000;15(8):1228-1231.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/10910450/pubmed\" target=\"_blank\" id=\"10910450\">10910450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18790207\"></a>Zhu B, Liu Z, Wu C, Wang P, Wang X, Xu H. Conversion from mycophenolate mofetil to azathioprine in renal allograft [corrected] patients within the first month posttransplantation. <i>Transplant Proc</i>. 2008;40(7):2258-2261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/azathioprine-drug-information/abstract-text/18790207/pubmed\" target=\"_blank\" id=\"18790207\">18790207</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9026 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708623\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F138216\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F138217\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F138263\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F138221\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F49335045\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F138222\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F138223\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673236\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F6730683\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F138195\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F138180\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F24672764\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F138198\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130888\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F138197\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475162\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F138271\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F138187\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F138202\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F138184\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298801\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F138189\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F138191\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1620142\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F1620144\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F138193\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F138183\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F138201\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F138204\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F138206\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9026|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=azathioprine-patient-drug-information\" class=\"drug drug_patient\">Azathioprine: Patient drug information</a></li><li><a href=\"topic.htm?path=azathioprine-pediatric-drug-information\" class=\"drug drug_pediatric\">Azathioprine: Pediatric drug information</a></li></ul></div></div>","javascript":null}